Amisulpride versus fluoxetine in dysthymia: Preliminary results of a double-blind comparative study

E. Smeraldi, E. Haefele, G. Crespi, G. L. Casadei, F. Biondi, E. Vigorelli

Research output: Contribution to journalArticle

Abstract

The efficacy and safety of low doses of amisulpride (50 mg/day) and of fluoxetine (20 mg/day) were compared respectively in 139 and 129 outpatients with dysthymia during three months in a multi-centre double-blind trial. No statistically significant difference between the two groups was found in the number of responders at study-end with the Montgomery and Asberg Depressive Rating Scale, which was the main criterion for efficacy. In addition, amisulpride was well tolerated. These preliminary results suggest that low doses of amisulpride may be effective in the treatment of dysthymic patients.

Original languageEnglish
JournalEuropean Psychiatry
Volume11
Issue numberSUPPL. 3
DOIs
Publication statusPublished - 1996

Keywords

  • amisulpride
  • benzamide
  • dysthymia
  • fluoxetine
  • treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Amisulpride versus fluoxetine in dysthymia: Preliminary results of a double-blind comparative study'. Together they form a unique fingerprint.

  • Cite this

    Smeraldi, E., Haefele, E., Crespi, G., Casadei, G. L., Biondi, F., & Vigorelli, E. (1996). Amisulpride versus fluoxetine in dysthymia: Preliminary results of a double-blind comparative study. European Psychiatry, 11(SUPPL. 3). https://doi.org/10.1016/0924-9338(96)85189-3